October 8, 2010 – Siemens PETNET Solutions has expanded its imaging biomarker capabilities in Nottingham, England and can now produce new biomarkers as investigational medicine products (IMP) in the United Kingdom.
The IMPs include a hypoxic agent that can identify tumor tissues with low oxygen supply and an amyloid agent for PET imaging of ß-amyloid deposits in the brain.
For more information: www.siemens.com/healthcare
June 1, 2026 — Serac Healthcare Ltd. has presented Phase 2 data showing that SPECT-CT imaging with the radiotracer 99mTc ...
June 01, 2026 
May 29, 2026 — GE HealthCare recently announced that its MIM KineticID modeling software1 is now 510(k) pending with the ...
May 29, 2026 
The Society of Nuclear Medicine and Molecular Imaging's (SNMMI) 2026 Annual Meeting will take place May 30–June 2 in Los ...
April 07, 2026 
March 25, 2026 — Catalyst MedTech, a provider of nuclear medicine and molecular imaging solutions, has announced it is ...
April 06, 2026 
March 18, 2026 — FluoGuide A/S, a biotech company maximizing surgical outcomes in oncology, has announced that the U.S ...
March 24, 2026 
March 17, 2026 – The Center for Radiology Education (CRE) has announced a nationwide initiative to provide scholarships* ...
March 17, 2026 
Feb. 27, 2026 — A new targeted PET/CT tracer can detect treatment response in rheumatoid arthritis patients in as little ...
February 26, 2026 
Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM ...
February 03, 2026 
Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...
January 27, 2026 
Nov. 11, 2025 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released a position paper outlining ...
November 12, 2025 